Perrigo Company PLC (PRGO)
Receivables turnover
Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 4,428,700 | 4,556,100 | 4,655,500 | 4,653,900 | 4,630,300 | 4,558,900 | 4,451,700 | 4,401,300 | 4,343,800 | 4,203,200 | 4,138,700 | 4,323,300 | 4,494,300 | 4,732,300 | 5,063,300 | 5,096,600 | 5,074,000 | 5,003,900 | 4,837,400 | 4,709,800 |
Receivables | US$ in thousands | 726,000 | 780,000 | 739,600 | 737,800 | 754,100 | — | 697,100 | — | — | — | 652,900 | — | — | — | — | — | — | — | — | — |
Receivables turnover | 6.10 | 5.84 | 6.29 | 6.31 | 6.14 | — | 6.39 | — | — | — | 6.34 | — | — | — | — | — | — | — | — | — |
June 30, 2024 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $4,428,700K ÷ $726,000K
= 6.10
The receivables turnover for Perrigo Company PLC has shown consistency and stability over the past periods, with the ratio ranging between 5.84 and 6.39. This indicates that, on average, the company is able to convert its accounts receivable into cash approximately six times a year. A higher receivables turnover ratio generally suggests that the company efficiently collects payment from its customers and manages its credit policies effectively. The sustained levels of the receivables turnover ratio for Perrigo indicate a healthy liquidity position and effective credit management practices.
Peer comparison
Jun 30, 2024
Company name
Symbol
Receivables turnover
Perrigo Company PLC
PRGO
6.10
Abbott Laboratories
ABT
6.01
AbbVie Inc
ABBV
4.87
Alkermes Plc
ALKS
4.06
Amphastar P
AMPH
5.61
ANI Pharmaceuticals Inc
ANIP
2.80
Arcus Biosciences Inc
RCUS
29.25
Biomarin Pharmaceutical Inc
BMRN
3.83
Bristol-Myers Squibb Company
BMY
4.12
Catalent Inc
CTLT
4.76
Catalyst Pharmaceuticals Inc
CPRX
7.44